Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab vs PDT for Presumed Ocular Histoplasmosis
NCT00546936Phase 2Unknown
- Sponsor
- Barnes Retina Institute
- Start
- Oct 2007
- Primary completion
- Oct 2009
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ranibizumab in Ocular Histoplasmosis Syndrome (OHS) (2 arms), sponsored by Barnes Retina Institute. Primary endpoint: Mean change in visual acuity at 1 year. Status: unknown.
02
Drugs
ranibizumab
03
Conditions
Ocular Histoplasmosis Syndrome (OHS)
Beyond the preview
Go deeper on NCT00546936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00546936.